Macrocylic inhibitors of hepatitis C virus

Details Macrocylic inhibitors of hepatitis C virus Macrocylic inhibitors of hepatitis C virus

2006-07-28

2010-02-09

Tsang, Cecilia (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07659245

ABSTRACT:
Compounds of the formula I:and N-oxides, salts, and stereoisomers thereofwhereinA is OR1, NHS(═O)pR2; wherein;R1is hydrogen, C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl;R2is C1-C6alkyl, C0-C3alkylenecarbocyclyl, C0-C3alkyleneheterocyclyl;p is independently 1 or 2;n is 3, 4, 5 or 6;denotes an optional double bond;L is N or CRz;Rz is H or forms a double bond with the asterisked carbon;Rq is H or when L is CRz, Rq can also be C1-C6alkyl;Rr is quinazolinyl, optionally substituted with one two or three substituents each independently selected from C1-C6alkyl, C1-C6alkoxy, hydroxyl, halo, haloC1-C6alkyl, amino, mono- or dialkylamino, mono- or dialkylaminocarbonyl, C1-C6alkyl-carbonylamino, C0-C3alkylenecarbocyclyl and C0-C3alkyleneheterocyclyl;R5is hydrogen, C1-C6alkyl, C1-C6alkoxyC1-C6alkyl or C3-C7cycloalkyl;R6is hydrogen, C1-C6alkyl, C1-C6alkoxy, C0-C3alkylenecarbocyclyl, C0-C3alkylene-heterocyclyl, hydroxy, bromo, chloro or fluoro have utility in the treatment or prophylaxis of flaviviral infections such as HCV.

REFERENCES:
patent: 2004/0180815 (2004-09-01), Nakajima et al.
patent: WO 00/09543 (2000-02-01), None
patent: WO 02/59929 (2000-10-01), None
patent: WO 03/053349 (2003-07-01), None
patent: WO 03/087092 (2003-10-01), None
patent: WO 03/099274 (2003-12-01), None
patent: WO2004/072243 (2004-08-01), None
Brown, F., et al., Hydroxyacetophenone-Derived Antagonists of the Peptidoleukotrienes; J. Med. Chem., 1989, 32, pp. 807-826.
Dolby, L., et al., “Studies of the Synthesis of the B, C, and D Rings of Gibberellie Acid”, in J. Org. Chem. 36 (1971) 1277-1285.
Goodman and Gillman's “The Pharmacological Basis of Therapeutics” Eighth Edition, McGraw-Hill, Inc., Health Professions Division, p. 1-20 (Title Page, Table of Contents), date: 1990.
Greene, “Protective Groups in Organic Chemistry”, Wiley & Sons, New York (1999) and “The Peptides: Analysis, Synthesis, Biology”, vol. 9, Academic Press, NY (1987) Title Page and Table of Contents.
Huang, et al., “Olefin Metathesis-Active Ruthenium Complexes Bearing a Nucleophilic Carbene Ligand” J. Am. Chem. Soc. 1999 121, p. 2674-2678.
Kingsbury, J., “A Recyclable Ru-Based Metathesis Catalyst”, et al., J. Am. Chem. Soc. 1999, 121, p. 791-799.
Krchnak, V. et al., “Polymer-Supported Mitsunobu Ether Formation and its Use in Combinatorial Chemistry”, Tetrahedron Letters, vol. 36, No. 35, p. 6193-6195, 1995.
Krieger, N., et al., “Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations”, Journal of Virology, May 2001, pp. 4614-4624.
Lohmann, V., et al., “Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line”, Science 285, 1999, pp. 110-113.
Miller, S., et al., “Application of Ring-Closing Metathesis to the Synthesis of Rigidified Amino Acids and Peptides”, J. Am. Chem. Soc. 1996, 118, p. 9606-9614.
Mitsunobu, Synthesis, Jan. 1-28, (1981).
Rano, T. et al., “Solid Phase Synthesis of Aryl Ethers via the Mitsunobu Reaction”, Tetrahedron Letters, vol. 36, No. 22, pp. 3789-3792, 1995.
Richter, L. et al, “A Surprising Observation about Mitsunobu Reactions in Solid Phase Synthesis”, Tetrahedron Letters, vol. 35, No. 27, p. 4705-4706, 1994.
Smith, E.M., et al., “Synthesis and Pharmacological Activity of Anagiotensin converting Enzyme Inhibitors: N-(Mercaptoacy)-4-substituted-(S)-Prolines”, J. Med. Chem. (1988), 31, 875-885.

Affiliated with

Also associated with

Rating

Macrocylic inhibitors of hepatitis C virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Macrocylic inhibitors of hepatitis C virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocylic inhibitors of hepatitis C virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4197312